Targeting Anti-HLA Class I and II Antibodies with CAR-B Cell Therapy: A Novel Strategy to Mitigate Graft Rejection and Platelet Refractoriness
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Alloimmune responses mediated by anti-HLA (human leukocyte antigen) antibodies are significant barriers to successful transplantation and transfusion therapies. Current immunosuppressive strategies target broad components of the immune system, often leading to non-specific effects, such as increased susceptibility to infections and malignancies. Here, we propose a novel therapeutic approach using Chimeric Antigen Receptor (CAR)-B cells engineered to target anti-HLA Class I and II antibodies. By specifically neutralizing these antibodies, CAR-B cell therapy has the potential to mitigate immune responses in allogeneic transplantation and transfusion, reducing the incidence of graft rejection and transfusion reactions. It will also neutralize the T cell response by binding to reactive T cells against donor HLA molecules. In this article, we discuss the rationale, design, and anticipated outcomes of this innovative therapy.
